Abstract
Prolonged B-cell depletion due to anti-CD20 monoclonal antibody (mAbs) therapy impairs the adaptive immune response, causing severe manifestations during COronaVIrus Disease-2019 (COVID-19). The cases of two patients under anti-CD20 therapy who experienced prolonged and severe COVID-19 successfully treated with mAbs against Severe Acute Respiratory Syndrome-CoV-2 spike proteins are reported.
Keywords: Anti-CD20 therapy; B-cell depletion; Prolonged infection; SARS-CoV-2 infection.
All Keywords
【저자키워드】 SARS-COV-2 infection, anti-CD20 therapy, B-cell depletion, Prolonged infection, 【초록키워드】 COVID-19, coronavirus disease, coronavirus, therapy, severe COVID-19, SARS-COV-2 infection, monoclonal antibody, anti-CD20 therapy, Spike protein, Severe acute respiratory syndrome, Patient, Adaptive immune response, respiratory, mAbs, anti-CD20, mAb, B-cell, Prolonged infection, Prolonged, Spike proteins, manifestation, two patients, reported, treated, impair, 【제목키워드】 Infection, Patient, Prolonged, approach, severe SARS-CoV-2,
【저자키워드】 SARS-COV-2 infection, anti-CD20 therapy, B-cell depletion, Prolonged infection, 【초록키워드】 COVID-19, coronavirus disease, coronavirus, therapy, severe COVID-19, SARS-COV-2 infection, monoclonal antibody, anti-CD20 therapy, Spike protein, Severe acute respiratory syndrome, Patient, Adaptive immune response, respiratory, mAbs, anti-CD20, mAb, B-cell, Prolonged infection, Prolonged, Spike proteins, manifestation, two patients, reported, treated, impair, 【제목키워드】 Infection, Patient, Prolonged, approach, severe SARS-CoV-2,
{{{ 추상적인 }}}
항-CD20 단클론항체(mAbs) 요법으로 인한 장기간의 B 세포 고갈은 적응 면역 반응을 손상시켜 코로나바이러스 감염증-2019(COVID-19) 동안 심각한 증상을 유발합니다. 중증 급성 호흡기 증후군-CoV-2 스파이크 단백질에 대한 mAb로 성공적으로 치료된 장기간의 중증 COVID-19를 경험한 항-CD20 요법을 받는 2명의 환자의 사례가 보고되었습니다.
{{ 키워드: }} 항-CD20 요법; B 세포 고갈; 장기간의 감염; SARS-CoV-2 감염.